Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for hospital use.
The actual benefit is substantial.
Clinical Added Value
AFINITOR offers a minor IAB (grade IV) in treatment strategy in the treatment of advanced renal cancer following failure of VEGF-targeted therapy.
Évaluation des médicaments